The Medical Letter on Drugs and Therapeutics
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old
Download PDF:   US English
Med Lett Drugs Ther. 2021 May 31;63(1625):81
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
Additional Contributor(s)
  • Michael Viscusi, Pharm.D., Associate Editor: no disclosure or potential conflict of interest to report
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy and safety of the Pfizer/BioNTech mRNA-based COVID-19 vaccine in adolescents 12-15 years old.
 Select a term to see related articles  COVID-19   Pediatrics   vaccines 

On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1 The vaccine has been authorized for use in persons ≥16 years old since December 2020.2

Expansion of the EUA was based on the results of an observer-blind trial (summarized in the FDA Fact Sheet) in 2260 adolescents 12-15 years old who were randomized 1:1 to receive the Pfizer/BioNTech vaccine or placebo at 0 and 3 weeks. There were 0 cases of COVID-19 with onset ≥7 days after the second dose among SARS-CoV-2-naive subjects who received the vaccine and 16 cases among those who received placebo. Compared to persons 16-25 years old who received the Pfizer/BioNTech vaccine, vaccinated adolescents 12-15 years old had numerically higher geometric mean titer levels of SARS-CoV-2 neutralizing antibodies (1239.5 vs 705.1) and similar adverse effects.3

With the expansion of the EUA, the FDA has added a warning to the vaccine Fact Sheet describing a risk of syncope following injection; the risk is higher in adolescents than in adults.3 Clinical trials evaluating use of the vaccine in children 6 months to 11 years old are ongoing.4

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article